medigraphic.com
ISSN 1561-2988 (Print)

2015, Number 2

<< Back Next >>

Rev Cubana Farm 2015; 49 (2)

Evaluation of the antitumor effect of nimotuzumab combined with radiochemotherapy in treatment of esophageal tumors

Saborido ML, Soriano GJL, Álvarez GS, González HZ, Riquelme AI

Language: Spanish
References: 48
Page: 254-270
PDF size: 236.28 Kb.


ABSTRACT

Introduction: esophageal cancer in Cuba is one of the first five causes of death from tumors. The treatment includes chemotherapy, radiotherapy and surgery as well as the discovery of new potential targets for immunotherapy such as the epidermal growth factor receptor. The Cuban monoclonal antibody AcM HR3 (nimotuzumab) is studied at present internationally.
Objective: to evaluate the efficacy and safety of nimotuzumab combined with radiochemotherapy in inoperable esophageal tumors and to compare it with the ordinary treatment given to patients seen at "Hermanos Ameijeiras" hospital from December 2005 to June 2010.
Method: open, controlled, randomized clinical study was designed for two groups of patients, one with radiochemotherapy plus biotherapy and the other one with radiochemotherapy. The main variable was the clinical response with which the tumor reduction is classified in accordance with the RECIST criteria: complete remission, partial remission, disease stabilization and progression. Toxicity tests evaluated the adverse events that occurred in patients of each of the groups.
Results: regarding the objective response, a higher proportion was reached in the group with nimotuzumab (88,9 %) against the control group (22,2 %), with statistically significant difference between both groups of patients equal to 66,7 %. Cough, insomnia, gastrointestinal problems and retrosternal pain were frequent in the treatment group whereas the control group suffered gastrointestinal disturbances and asthenia more frequently.
Conclusions: the patients treated with nimotuzumab presented better index of objective response and of disease control and its administration was safe when combined with the set therapy for treatment of inoperable esophageal cancer in line with the Cuban therapeutic standards.


REFERENCES

  1. Ferraina P, Oria A. Cirugía de Michans. 5ta ed. Buenos Aires: Editorial El Ateneo; 1997:404-9.

  2. Devesa SS, Blot WJ, Fraumeni JFJr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049-53.

  3. Jemal A, Murray T, Ward E. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.

  4. Schneider Bryan J, Urba Susan G. Preoperative chemoradiation for the treatment of locoregional esophageal cancer. The standard of Care? Semin Radiat Oncol. 2006;17:45-52.

  5. Andre T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prevot S. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer. 2000;86(2):174-81.

  6. Arteaga CL.The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. Semin Oncol. 2002;29(5 Suppl 14):3-9.

  7. Oficina Nacional de Estadísticas e Información. Anuario Estadístico de Cuba, edición 2013. La Habana: OFN; 2013.

  8. Alfonso L. Oncología preguntas y respuestas. Capítulo 12. Cánceres del tubo digestivo y glándulas anexas. Esófago, estómago, intestino delgado, colon, recto, ano, hígado y páncreas exocrino. Barcelona-Philadelphia: Editorial Prous Science; 2001. p. 331-74.

  9. van Meerten E, van der Gaast A. Systemic treatment for oesophageal cancer. Eur J Cancer. 2005;41:664-72.

  10. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007 June;8:545-53.

  11. Hulscher JB, van Sandick JW, de Boer AG. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662-9.

  12. Altorki N, Skinner D. Should en bloc esophagectomy be the standardof care for esophageal carcinoma? Ann Surg. 2001;234:581-7.

  13. Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resectionfor esophageal carcinoma. Ann Thorac Surg. 2004;78:1177-83.

  14. Mariette C. Surgery alone in the curative treatment of localised oesophagealcarcinoma. Eur J Surg Oncol. 2004;30:869-76.

  15. Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A, Triboulet JP. Impact of preoperative radiochemotherapy on postoperativecourse and survival in patients with locally advanced squamous celloesophageal carcinoma. Br J Surg. 2006;93:1077-83.

  16. Mariette C, Triboulet JP. Is preoperative chemoradiation eff ective in treatment of oesophageal carcinoma? Lancet Oncol. 2005;6:635-7.

  17. Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, et al. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995;72(4):928-33.

  18. Wallace PK, Romet-Lemonne JL, Chokri M, Kasper LH, Fanger MW, Fadul CE. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer Immunol Immunother. 2000;49(9):493-503.

  19. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22:1646-54.

  20. Verduzco-Rodriguez L, Aguirre-Gonzalez EH, Verduzco-Aguirre HC. Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. Hematol Oncol Stem Cell Ther. 2011;4:182-4.

  21. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR. Cancer Biol Ther. 2010;10.

  22. Ramos TC, Figueredo J, Catala M. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther. 2006;5:375-9.

  23. Crombet T. Use the humanized anti-EGFR MAb (nimotuzumab) and radiotherapy for the treatment of high grade glioma patients European Journal of Cancer. 2008 suppl;6:168.

  24. Crombet T, Cabanas R, Alert J. Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: preliminary results from a phase II study. Eur J Cancer Suppl. 2009:7.

  25. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG. Treatment of malignant, nonresectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 2012;13:600-5.

  26. Strumberg D, Schultheis B, Scheulen ME. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8.

  27. Macias A, Neninger E, Santiesteban E. Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases. Eur J Cancer. 2008;Suppl:160-1.

  28. National Cancer Institute. Common Terminology Criteria for Adverse Eventes (CTCAE) Version 4.0. Published: May 28, 2009. [citado 5 mayo 2014]. Disponible en: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_5x7.pdf

  29. Fiorica F, Di Bona D, Schepis F. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925-30.

  30. Ng T, Dipetrillo T, Purviance J, Safran H. Multimodality treatment of esophageal cancer: a review of the current status and future directions. Curr Oncol Rep. 2006;8:174-82.

  31. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009 Oct;20(10):1667-73.

  32. Bedenne L, Michel P, Bouche O. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-8.

  33. Stahl M, Stuschke M, Lehmann N. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2006;24:531.

  34. Stahl M, Wilke H, Lehmann. Long-term results of a phase II study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. J Clin Oncol. 2008;26:4530.

  35. Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1667- 1174.

  36. Munro AJ. Oesophageal cancer: a view over overviews. The Lancet. 2004;364(9434):566-8.

  37. Ishikura S, Nikei K, Ohtsu A. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697-702.

  38. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus. JCO. 2003 Jul 15 [citado 5 Mayo 2014];21(14):2697-2702. Disponible en: http://jco.ascopubs.org/content/21/14/2697.abstract

  39. Wong RK, Malthaner RA, Zuraw L. Cancer care ontario practice guidelines initiative gastrointestinal c ancer disease site group: combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 2003;55:930-42.

  40. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of prospective randomized trial (Radiation Therapy Oncology Group 85-01). JAMA. 1999;281:1623-7.

  41. Crombet T. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9).

  42. Solomon MT, Selva JC, Figueredo J. Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients. J Clin Oncol 2012;30.

  43. Macias A, Neninger E, Santiesteban E. Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases. Eur J Cancer. 2008;Suppl:160-1.

  44. Soriano JL, Ramos Suzarte M, Wilkison B, Viada CE, Garcia E, Jiménez G, et al. Tratamiento del cáncer de mama avanzado con el anticuerpo monoclonal hR3 en combinación con doxorrubicina y ciclofosfamida. EC Fase I. Ciudad de La Habana: CIM; 2003.

  45. Crombet Ramos T, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of High-Grade Glioma Patients with the Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Antibody h-R3 Report from a Phase I/II Trial. Cancer Biology & Therapy 2006 April; 5(4): 375-379.

  46. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, et al. Cetuximab with concurrent chemoradiation for esophagogastriccancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391-5.

  47. Saltz L, Meropol NJ, Loehrer PJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-8.

  48. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45.




2020     |     www.medigraphic.com